Developing Drug Pricing Strategies in an Evolving Federal Policy Environment: Health Care Reform and Beyond

April 29, 2014 11:30am

Steven K. Stranne MD, JD
Shareholder
Polsinelli Shughart PC

• The potential impacts of federal policy developments
• The possibility of changes to the average sales price (ASP) methodology
• The relevant provisions and ongoing implementation of the Affordable Care Act
• Potential impacts of innovative delivery models, including but not limited to accountable care organizations
• Comparative effectiveness research
• Issues arising from federal efforts to address drug shortages
• Considerations related to the policy debates over the sustainable growth rate (SGR) formula and other relevant issues